Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation

1 Feb 2003

Abstract excerpt

It has been approximately ten years since the Food and Drug Administration (FDA) approved paclitaxel for the treatment of platinum resistant epithelial ovarian carcinoma. Since the approval, the drug has found therapeutic applications in a variety of schedules and in a wide variety of epithelial malignancies. Its novel mechanism of action provided the hope that it would demonstrate anti-neoplastic activity in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 12570657
DOI: 10.2174/1568009033333754

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic ManipulationPMID 12570657Read ↗

Key genes and molecular mechanisms related to Paclitaxel ResistanceSemantic proximity Read ↗

Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.Semantic proximity Read ↗

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.Semantic proximity Read ↗

Class III β-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer PatientsSemantic proximity Read ↗

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.Semantic proximity Read ↗

Chemoresistance to paclitaxel in human ovarian xenografts : the role of apoptosis-regulating proteinsSemantic proximity Read ↗

Molecular effects of paclitaxel: Myths and reality (a critical review)Semantic proximity Read ↗

Human mutations that confer paclitaxel resistance.Semantic proximity Read ↗

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicinSemantic proximity Read ↗

Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation TaxanesSemantic proximity Read ↗

Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.Semantic proximity Read ↗

Mechanisms regulating resistance to inhibitors of topoisomerase IISemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.